Dong-E-E-Jiao (SHE:000423) expects an attributable profit of between 1.5 billion yuan and 1.6 billion yuan for the year 2024, up from 1.15 billion yuan a year prior, a Friday bourse filing by parent China Resources Pharmaceutical Group (HKG:3320) said.
The pharmaceutical company's higher anticipated profit was mainly due to a steady growth in operating performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.